received U.S. Food and Drug Administration 510(k) intermediate risk clearance for use in "surgical
applications where soft tissue is being approximated," and 5 years since the first publications on the feasibility of its use for left atrial appendage (LAA) exclusion (1) . As an alternative to systemic anticoagulation for at-risk patients with atrial fibrillation, the initial published data in 89 patients from Poland was encouraging (2) . Acute complete LAA closure was achieved in 92% with an overall complication rate of only 3.3%. Accordingly, the use of Lariat technology for LAA closure began to rapidly expand.
However, like many new interventional technologies, additional real-world experience demonstrated more sobering results. In our own multicenter retrospective series, the rate of acute LAA closure was high (93%) but nearly one-quarter of patients developed reconstitution of LAA flow ("LAA leak") at 3 months.
Furthermore, 20% of patients developed pericardial effusions requiring drainage and 9% of patients experienced LAA perforation (of which 2 required urgent cardiac surgery) (3). More recently, a systematic review of published reports confirmed the relative effectiveness of the Lariat for achieving acute LAA closure (90%), but it also reiterated the concerning safety profile (4) . Most notable was the need for urgent cardiac surgery in 2.3% of patients. It should also be noted that in the most of the previously published series, a majority of patients (>60%) were receiving oral anticoagulation prior to the procedure, and a significant number of patients remained on oral anticoagulation after the procedure, making interpretation of the impact of the Lariat device on the rate of stroke and system embolism rates difficult, if not impossible, to assess (3, 5) . Common to all of these studies is the retrospective design and lack of prespecified safety and efficacy endpoints that thereby further obscure assessment of the risk-to-benefit ratio.
It is in this context that Sievert et al. (6) have no relationships relevant to the contents of this paper to disclose. Atrial Appendage Closure Technology) study (7) . This is the first study of the Lariat device using a multicenter prospective design and pre-specified safety and efficacy endpoints; thus, this study represents the strongest quality data to date. However, due to the lack of randomization and an active comparator cohort, the study fails to provide direct evidence that
Lariat is responsible for the low stroke and systemic embolization rate observed (i.e., it does not prove that successful closure of the LAA with the Lariat device prevents AF-related embolic events).
With respect to establishment of safety of the Lariat device, this study falls short of appeasing concerns.
The 11.5% complication rate is attributable to pericarditis persisting >2 days in 5.9% of patients, requirement for emergency surgery in 1.4%, and death in 1.8%. Although some of these rates are slightly lower than reported in other studies, the findings should be interpreted in the context that safety events were adjudicated by investigators rather than by an independent clinical events committee, thereby introducing the potential for interpretation bias. For example, all safety events were attributed to the procedure rather than the device, which is conceivable but inconsistent with real-world experience (3-5).
Eliminated in this study is major bleeding, which has been reported in up to 9% of procedures (5) 
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